论文部分内容阅读
目的评价艾迪注射液联合肝动脉化疗栓塞(TACE)治疗中晚期原发性肝癌(HCC)的临床疗效和毒副反应。方法将80例HCC患者随机分为2组均接受超选择性TACE。治疗组肝动脉化疗栓塞术后给予艾迪注射液80 ml加0.9%氯化钠500 ml静脉滴注;对照组仅行常规介入肝动脉化疗栓塞术。结果治疗组在肿瘤体积缩小有效率、生活质量改善Karnofsky评分、血清AFP浓度下降情况高于对照组(P<0.05)。毒副反应无差异。结论艾迪注射液联合TACE是一种安全、有效的治疗中晚期原发性肝癌的方法。
Objective To evaluate the clinical efficacy and side effects of Aidi injection combined with transcatheter arterial chemoembolization (TACE) in the treatment of advanced primary hepatocellular carcinoma (HCC). Methods Eighty patients with HCC were randomly divided into two groups and received TACE. In the treatment group, Aidi injection 80 ml plus 0.9% sodium chloride 500 ml was given intravenously after transcatheter arterial chemoembolization. The control group received routine hepatic arterial chemoembolization only. Results The effective rate of tumor volume reduction, Karnofsky score of quality of life improvement, serum AFP concentration decrease in treatment group were higher than those in control group (P <0.05). No difference in toxic and side effects. Conclusion Aidi injection combined with TACE is a safe and effective method for the treatment of advanced primary liver cancer.